Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anusha S Thomas

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Cancers|May 16, 2023
Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and ColitisMiho Kono, Malek Shatila, Guofan Xu, et al.
Journal of Cancer Research and Clinical Oncology|August 16, 2022
Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitisBarbara Hollander, Shruti Khurana, Jake S Jacob, et al.
Journal of Cancer|October 18, 2021
Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent <i>Clostridioides difficile</i> in cancer patientsHiba Ali, Shruti Khurana, Weijie Ma, et al.
Journal for Immunotherapy of Cancer|January 13, 2021
Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitisFangwen Zou, Xuemei Wang, Isabella C Glitza Oliva, et al.
Annals of Gastroenterology|September 5, 2022
Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomesKevin Yu, Antony Mathew, Fiyinfoluwa Abraham, et al.
Journal of Cancer Research and Clinical Oncology|November 30, 2022
Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitorsAustin R Thomas, Cynthia Liu, Yi T Tong, et al.
Annals of Gastroenterology|July 5, 2022
<i>Clostridioides difficile</i> infection in cancer patients receiving immune checkpoint inhibitorsShaleen Vasavada, Kavea Panneerselvam, Rajan Amin, et al.
Annals of Gastroenterology|January 3, 2023
Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapyAndrew G Kuang, Wasay Mohajir, Kavea Panneerselvam, et al.
American Journal of Clinical Oncology|June 6, 2021
Clinical Characteristics and Outcomes of Eosinophilic Colitis in Patients With CancerShruti Khurana, Hamzah Abu-Sbeih, Weijie Ma, et al.
Annals of Gastroenterology|September 5, 2022
Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitorsKavea Panneerselvam, David Szafron, Rajan N Amin, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Cancers|May 16, 2023
Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and ColitisMiho Kono, Malek Shatila, Guofan Xu, et al.
Journal of Cancer Research and Clinical Oncology|August 16, 2022
Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitisBarbara Hollander, Shruti Khurana, Jake S Jacob, et al.
Journal of Cancer|October 18, 2021
Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent <i>Clostridioides difficile</i> in cancer patientsHiba Ali, Shruti Khurana, Weijie Ma, et al.
Journal for Immunotherapy of Cancer|January 13, 2021
Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitisFangwen Zou, Xuemei Wang, Isabella C Glitza Oliva, et al.
Annals of Gastroenterology|September 5, 2022
Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomesKevin Yu, Antony Mathew, Fiyinfoluwa Abraham, et al.
Journal of Cancer Research and Clinical Oncology|November 30, 2022
Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitorsAustin R Thomas, Cynthia Liu, Yi T Tong, et al.
Annals of Gastroenterology|July 5, 2022
<i>Clostridioides difficile</i> infection in cancer patients receiving immune checkpoint inhibitorsShaleen Vasavada, Kavea Panneerselvam, Rajan Amin, et al.
Annals of Gastroenterology|January 3, 2023
Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapyAndrew G Kuang, Wasay Mohajir, Kavea Panneerselvam, et al.
American Journal of Clinical Oncology|June 6, 2021
Clinical Characteristics and Outcomes of Eosinophilic Colitis in Patients With CancerShruti Khurana, Hamzah Abu-Sbeih, Weijie Ma, et al.
Annals of Gastroenterology|September 5, 2022
Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitorsKavea Panneerselvam, David Szafron, Rajan N Amin, et al.
Pageof 5